Eli Lilly Nears AtaiBeckley Deal as Big Pharma Pushes Into Psychedelic Medicine in 2026
Updated
Updated · Bloomberg · Jul 16
Eli Lilly Nears AtaiBeckley Deal as Big Pharma Pushes Into Psychedelic Medicine in 2026
3 articles · Updated · Bloomberg · Jul 16
Summary
Eli Lilly is in talks to acquire New York-based psychedelic drugmaker AtaiBeckley, with an announcement possible as soon as this week, according to people familiar with the matter.
The potential takeover would deepen Lilly’s reach in psychedelic medicine, a once-fringe field now drawing growing interest from large pharmaceutical companies.
AtaiBeckley’s location in New York and Lilly’s move toward a near-term deal suggest the talks have advanced beyond early-stage interest.
A completed acquisition would mark another sign that mainstream drugmakers are moving to secure positions in emerging mental-health treatment platforms.